(Total Views: 469)
Posted On: 03/08/2024 9:55:22 AM
Post# of 148863
FDA: alzheimers drug pause on donanemab
FDA apparently doing their job.
Eli Lilly’s donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug’s safety and efficacy.
mab infusion once a month, still focusing on theories that plaque based buildups are the cause of alzheimers. but didnt we conclude that the plaque drugs didnt do anything significant? and "The drugs also carry significant safety risks, including swelling and bleeding in the brain." ?????
https://www.nytimes.com/2024/03/08/health/alz...nemab.html
FDA walking softly in the alzheimers world as the complete failure and embarrassment of aduhelm. still no real repercussions from the obvious and clear corruption of that approval = FDA (honey badger) dont care...where are the lawyers?
the day will come for LL's turn at bat. scouts are out there hope they are paying attention.
FDA apparently doing their job.
Eli Lilly’s donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug’s safety and efficacy.
mab infusion once a month, still focusing on theories that plaque based buildups are the cause of alzheimers. but didnt we conclude that the plaque drugs didnt do anything significant? and "The drugs also carry significant safety risks, including swelling and bleeding in the brain." ?????
https://www.nytimes.com/2024/03/08/health/alz...nemab.html
FDA walking softly in the alzheimers world as the complete failure and embarrassment of aduhelm. still no real repercussions from the obvious and clear corruption of that approval = FDA (honey badger) dont care...where are the lawyers?
the day will come for LL's turn at bat. scouts are out there hope they are paying attention.
(4)
(0)Scroll down for more posts ▼
